Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Capital Expenditures (2016 - 2021)

BioCorRx's Capital Expenditures history spans 7 years, with the latest figure at $2017.0 for Q1 2021.

  • For Q1 2021, Capital Expenditures changed N/A year-over-year to $2017.0; the TTM value through Dec 2021 reached $2017.0, changed N/A, while the annual FY2021 figure was $2017.0, N/A changed from the prior year.
  • Capital Expenditures for Q1 2021 was $2017.0 at BioCorRx, up from -$6400.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $6400.0 in Q3 2020 and bottomed at -$59326.0 in Q3 2018.
  • The 4-year median for Capital Expenditures is -$6400.0 (2020), against an average of -$20098.4.
  • The largest annual shift saw Capital Expenditures plummeted 5486.18% in 2019 before it surged 639900.0% in 2020.
  • A 4-year view of Capital Expenditures shows it stood at -$984.0 in 2018, then tumbled by 5486.18% to -$54968.0 in 2019, then soared by 88.36% to -$6400.0 in 2020, then soared by 131.52% to $2017.0 in 2021.
  • Per Business Quant, the three most recent readings for BICX's Capital Expenditures are $2017.0 (Q1 2021), -$6400.0 (Q4 2020), and $6400.0 (Q3 2020).